Work

A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7599

Authors: Giorgio Scagliotti, Dong-Wan Kim, Alice Tsang Shaw, Sai-Hong Ignatius Ou, Gregory J. Riely, Scott N. Gettinger, Benjamin Besse, Michael Thomas, Ravi Salgia, Keith D. Wilner, Cynthia Huang Bartlett, Anna Polli, David R. Gandara

Institutions: University of Turin, Seoul National University, Seoul National University Hospital, Massachusetts General Hospital, University of California, Irvine, Memorial Sloan Kettering Cancer Center, Yale University, Institut Gustave Roussy, Heidelberg University, University of Chicago, Pfizer (United States), UC Davis Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2902411375

Cites:

Cited by: 6

Related to: 10